Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Sees Large Decrease in Short Interest
by Scott Moore · The Cerbat GemBiodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Get Free Report) was the recipient of a significant decline in short interest in the month of May. As of May 29th, there was short interest totaling 10,140 shares, a decline of 51.5% from the May 14th total of 20,907 shares. Based on an average daily trading volume, of 16,983 shares, the short-interest ratio is presently 0.6 days. Approximately 0.5% of the company’s shares are sold short.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on the company. Wall Street Zen cut Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 30th. Weiss Ratings cut Biodexa Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, June 3rd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Biodexa Pharmaceuticals presently has a consensus rating of “Sell”.
Get Our Latest Research Report on BDRX
Biodexa Pharmaceuticals Trading Down 1.6%
Shares of NASDAQ:BDRX traded down $0.05 during midday trading on Friday, reaching $3.03. 12,105 shares of the company’s stock traded hands, compared to its average volume of 22,841. Biodexa Pharmaceuticals has a one year low of $2.86 and a one year high of $66.50. The stock has a 50 day moving average of $3.52 and a 200 day moving average of $8.76.
Biodexa Pharmaceuticals (NASDAQ:BDRX – Get Free Report) last announced its quarterly earnings results on Friday, March 27th. The company reported $3.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $3.53.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC bought a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals accounts for approximately 0.6% of Sabby Management LLC’s portfolio, making the stock its 10th biggest position. Sabby Management LLC owned approximately 28.04% of Biodexa Pharmaceuticals at the end of the most recent quarter. 17.51% of the stock is owned by institutional investors and hedge funds.
Biodexa Pharmaceuticals Company Profile
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.